The primary objective of this study is to determine whether data acquired from a remote monitoring approach can reliably identify and track motor symptoms in prodromal PD and clinical PD. The study is a one-year longitudinal biomarker study recruiting idiopathic RBD patients, Parkinson's Disease patient and healthy controls. All participants receive a smartphone with the Roche PD Mobile Application, complete a number of active tests daily and their movements will be remotely monitored. Participants will undergo additional neurological exams and DaT-SPECT and MRI imaging in the study. A second objective of this study will be to validate an immunohistochemistry skin biopsy assay for the detection of pathological alpha-synuclein diagnostic of PD, in the peripheral nerves of the skin.
Study Type
OBSERVATIONAL
Enrollment
295
Observational
Participants may consent to additional skin biopsy at baseline and at the one-year follow-up. Skin will be taken paravertebrally at approximately the C8 level.
Pacific Parkinson's Research Centre
Vancouver, British Columbia, Canada
RECRUITINGCentre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
RECRUITINGThe Neuro
Montreal, Quebec, Canada
RECRUITINGThe Neuro
Montreal, Quebec, Canada
RECRUITINGCentre de recherche du CHU de Québec-Université Laval (CHUQ)
Québec, Canada
RECRUITINGDigital Biomarkers
Changes in continuous sensor-based measurements derived from Roche PD MobileApplication, with active testing and passive monitoring in idiopathic RBD and clinical PD (1 month in Healthy Controls)
Time frame: 12 months
alpha-synuclein deposition in skin biopsy
Frequency of pathological alpha-synuclein deposition in the skin biopsy assay in idiopathic RBD and clinical PD and HC (optional study procedure)
Time frame: 12 months
Changes in sensor-based measurements and passive monitoring
Relationship between changes in continuous sensor-based measurements derived from Roche PD Mobile Application active testing and passive monitoring over 12 months in idiopathic RBD, clinical PD and HC and changes in clinical assessments
Time frame: 12 months
Correlation of sensor-based measurements and imaging outcomes
For idiopathic RBD patients only, correlation between sensor-based measurements derived from Roche PD Mobile Application active testing and passive monitoring and changes in MRI and DaT-SPECT outcome measures.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.